key: cord-0052840-3ya36au3
authors: Janse van Rensburg, Helena D.; Legoabe, Lesetja J.; Terre’Blanche, Gisella
title: C3 amino-substituted chalcone derivative with selective adenosine rA(1) receptor affinity in the micromolar range
date: 2020-11-17
journal: Chem Zvesti
DOI: 10.1007/s11696-020-01414-9
sha: 29e09d5dd0fe9b4b6306f6fc1894e44f0cb09e83
doc_id: 52840
cord_uid: 3ya36au3

ABSTRACT: To identify novel adenosine receptor (AR) ligands based on the chalcone scaffold, herein the synthesis, characterization and in vitro and in silico evaluation of 33 chalcones (15–36 and 37–41) and structurally related compounds (42–47) are reported. These compounds were characterized by radioligand binding and GTP shift assays to determine the degree and type of binding affinity, respectively, against rat (r) A(1) and A(2A) ARs. The chalcone derivatives 24, 29, 37 and 38 possessed selective A(1) affinity below 10 µM, and thus, are the most active compounds of the present series; compound 38 was the most potent selective A(1) AR antagonist (K(i) (r) = 1.6 µM). The structure–affinity relationships (SAR) revealed that the NH(2)-group at position C3 of ring A of the chalcone scaffold played a key role in affinity, and also, the Br-atom at position C3′ on benzylidene ring B. Upon in vitro and in silico evaluation, the novel C3 amino-substituted chalcone derivative 38—that contains an α,ß-unsaturated carbonyl system and easily allows structural modification—may possibly be a synthon in future drug discovery. GRAPHIC ABSTRACT: C3 amino-substituted chalcone derivative (38) with C3′ Br substitution on benzylidene ring B possesses selective adenosine rA(1) receptor affinity in micromolar range. [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11696-020-01414-9) contains supplementary material, which is available to authorized users.

In the human body, adenosine takes part in both physiologic and pathophysiologic processes (Boison 2018) . Most, if not all, of these actions are mediated by four cell surface receptors, denoted A 1 , A 2A , A 2B and A 3 (Fredholm et al. 1994 (Fredholm et al. , 2001 (Fredholm et al. , 2011 . Ensuing almost 100 years of research on adenosine and its receptors as well as the ligands that bind to these adenosine receptors (ARs), the potential of the adenosine Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1169 6-020-01414 -9) contains supplementary material, which is available to authorized users. system as a drug discovery target is evident (de Lera Ruiz et al. 2013) .

The A 1 AR has been cloned from different mammalian species, including humans (Müller 2001) and show structural homology among diverse mammalian species (Ralevic and Burnstock 1998) (although lower affinity for human than rat receptors have been reported) (Klotz et al. 1997) . A member of the seven transmembrane-spanning G-protein-coupled receptor superfamily (that preferentially couples to inhibitory G i/o heterotrimeric G-proteins) (Freissmuth et al. 1991; Munshi et al. 1991; Ralevic and Burnstock 1998) , the A 1 AR inhibits adenylate cyclase and decreases cyclic adenosine monophosphate (Londos et al. 1980; Van Calker et al. 1978) . Other second messenger systems may also be coupled to the A 1 AR, such as phospholipase C and several types of calcium and potassium channels (Ralevic and Burnstock 1998) . A 1 ARs are widely distributed in different mammalian species (Ralevic and Burnstock 1998) and ubiquitous within the central nervous system, with the highest density in the cerebral cortex, cerebellum, hippocampus, thalamus, brainstem and spinal cord (Dixon et al. 1996; Reppert et al. 1991) . These receptors are localized in the active zone of the presynaptic nerve terminal (Rebola et al. 2003; Swanson et al. 1995) , a highly specialized region of the cytoplasm that directly faces the synaptic cleft (Sankaranarayanan and Ryan 2007) .

At presynaptic nerve terminals, A 1 ARs play a role in the release of neurotransmitters (Dunwiddie 1985) . Adenosine acts by inhibiting cholinergic transmission, among other, via A 1 ARs (Phillis 1991 ). The cholinergic system has been associated with a number of cognitive functions, for example, learning and memory as well as emotion (Jackson 2011) .

Interaction between the adenosine and cholinergic system is regrettably controversial; on the one hand, administration of a selective A 1 AR agonist (e.g. CPA) caused learning and memory deficits, which may be prevented by a selective A 1 AR antagonist (e.g. DPCPX) (Normile and Barraco 1991) , and on the other hand, the said antagonist also caused learning and memory deficits (Vollert et al. 2013 )! Moreover, it was found that chronic treatment with A 1 AR modulators result in behavioural effects different from those observed following acute administration; therefore, particular caution is required in the development of adenosine-based strategies for the chronic treatment of neurodegenerative or cognitive disorders (Von Lubitz et al. 1993) . Other studies advocated the use of A 1 AR antagonists and considered the A 1 AR an interesting drug target for the development of cognitive enhancers based on the observation that A 1 AR antagonism positively modulated memory process (Maemoto et al. 2004; Normile and Barraco 1991; Pitsikas and Borsini 1997; Suzuki et al. 1993) .

Apart from learning and memory, adenosine and its receptors-specifically the A 1 AR-also modulate anxiety where blockade of the A 1 AR results in anxiolytic actions (Maemoto et al. 2004) . The A 1 AR agonist R-PIA exacerbated the effects of ethanol withdrawal, whereas the A 1 AR antagonist CPT improved these anxiogenic effects in the elevated plus-maze and light/dark test, relevant behavioural animal models of anxiety (Gatch et al. 1999) . These results suggest that A 1 AR antagonists, at some doses, may be useful for ameliorating the anxiogenic effects produced by ethanol withdrawal, although it does not appear useful for reducing ethanol consumption (Gatch et al. 1999 ). Furthermore, the widely used anxiolytic agents, benzodiazepines, block adenosine uptake (Noji et al. 2004 ) and decreased A 1 AR binding capacity in vivo at doses of clinical relevance (Kaplan et al. 1992) . As with the adenosine system and its effects on learning and memory, there is controversy: DPCPX did not affect the anxiety state of mice in the elevated plus-maze test (Jain et al. 1995) and A 1 AR knockout mice showed signs of increased anxiety in the light/dark test (Johansson et al. 2001) .

Adenosine and its analogues have been known to cause behavioural despair in animal models relevant to depression. The A 2A , rather than the A 1 , AR is involved in depression; based on evidence from pharmacology and A 2A AR knockout mice (Yacoubi et al. 2001) . (Additionally, the selective A 2A AR antagonist istradefylline not only improves motor fluctuations but also some non-motor symptoms of Parkinson's disease (PD); such as the mood disorder depressionthe most common non-motor symptom of PD (Aarsland et al. 2012; Nagayama et al. 2019) This is yet to be confirmed by a double-blind placebo-controlled trial (Nagayama et al. 2019) . Interestingly, the selective A 1 AR antagonist DPCPX enhanced the anti-depressant effects of selective serotonin re-uptake inhibitors (SSRIs) imipramine, escitalopram and reboxetine in mice behavioural tests (Szopa et al. 2018) ; nevertheless, the effects of atypical antidepressants agomelatine and tianeptine were increased, not by DPCPX, but by the selective A 2A AR antagonist DMPX (Szopa et al. 2019) .

The orally active and brain penetrable pyrazolopyridine derivative FR194921 (1) exhibits potent affinity for the A 1 AR (A 1 (h) K i = 2.9 nM) without affinity for the A 2A and A 3 ARs (Fig. 1 ). In addition, no species differences among human, rat and mouse were observed in the binding affinity profile of this compound (Maemoto et al. 2004) . After oral administration of FR194921 (1), hypolocomotion in rats caused by the A 1 AR agonist CPA was bettered demonstrating A 1 AR antagonism in vivo (Maemoto et al. 2004 ). Additionally, scopolamine-induced memory deficits (passive avoidance test) as well as anxiety (social interaction test and elevated plus-maze test) were also bettered by the said compound (1), without influencing general behaviour (Maemoto et al. 2004 ). FR194921 (1) showed no anti-depressant activity (forced swim test)-even at high doses. It may be said that FR194921 (1) shows promise in the treatment of memory deficits and anxiety (Maemoto et al. 2004) .

The role of A 1 AR antagonists in brain functioning is not yet fully understood, and at times, debatable-yet, selective A 1 AR antagonists have potential for the treatment of neurological and psychiatric conditions, as seen with the potent and selective A 1 AR antagonist FR184921 (1).

While diverse classes of A 1 AR antagonists have been documented since the discovery of the receptor and specific radiolabelled ligands, most of these compounds were derived from xanthine analogues which show poor water solubility and oral bioavailability, central nervous system penetration and considerable species differences in terms of receptor binding affinity (Maemoto et al. 1997) . Due to these undesirable physiochemical properties of xanthine derivatives, the focus has shifted from xanthine to non-xanthine based heterocycles as A 1 AR antagonists (de Lera Ruiz et al. 2013) .

The chemical structure 1,3-diphenyl-2-propen-1-oneperhaps better known by the general term "chalcone"-has attracted attention from both chemical (biosynthesis and synthesis) and biological standpoints; due to the wideranging pharmacological properties exhibited by these compounds (Mathew et al. 2019; Zhuang et al. 2017 ). These properties include anticancer, antileishmanial, antimalarial, antimicrobial, antiviral, antifungal, antioxidant, antihypertensive and antidiabetic biological activitiesto name a few (Batovska and Todorova 2010; Sahu et al. 2012; Karthikeyan et al. 2015; Singh et al. 2014; Zhou and Xing 2015) . Additionally, chalcones show potential in the treatment of neurological conditions by acting as anxiolytics and antidepressants, as well as the modulation of gamma-aminobutyric acid (GABA) receptors and the inhibition of acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and monoamine oxidase (MAO) (Mathew et al. 2019) . Of note, the chalcone-coumarin hybrid (2) possesses selective A 3 AR affinity (A 3 K i (h) = 5.2 µM) (Vazquez-Rodriguez et al. 2013) , the blockade of A 3 ARs may be advantageous in brain ischemia (Fig. 2) (Jacobson and Gao 2006) .

The term chalcone generally refers to chemicals with an α,ß-unsaturated carbonyl system; thus, the chalcone family has extensive structural diversity (Zhuang et al. 2017) . For example, the chalcone-based benzocycloalkanone derivatives are hybrid chalcones with the core scaffold of 1,3-diaryl-2-propen-1-one (Fig. 3) . Some of these compounds structurally related to chalcones include aurone derivatives, which also possess selective A 1 affinity [such as hispidol (3)] (Jacobson et al. 2002) and served as inspiration for the structurally related 2-benzylidene-1-tetralone (4-8) (Janse van Rensburg et al. 2017; Legoabe et al. 2018 ) and 2-benzylidene-1-indanone derivatives (9-12) (Janse van Rensburg et al. 2019a, b) , leading to compounds with selective affinity for the A 1 AR in the micromolar range.

The chemistry of chalcones is as attractive today as it was years ago; due to the open-chain model and the feature of skeletal modification to produce a new class of organic compounds such as isoxazole-, pyrazole-and indolebased chalcones. Heterocycles occupy a central position in medicinal chemistry and a number of both approved and potential drugs contain at least one heterocyclic nucleus (Khanam 2015; McGrath et al. 2010) . Based on the above and in continuation of the efforts to obtain heterocycles as A 1 and/or A 2A AR antagonists, simple chalcone derivatives (15-36) with either ring A or ring B substitutions as well as a series of novel C3 amino-substituted chalcone derivatives (37-41) with halogen (Br-, Cl-and F-atoms) substitutions on ring B and their regioisomers (42-47) were designed containing the basic chalcone scaffold as structural core. Herein the synthesis, characterization and evaluation, both in vitro and in silico, will be discussed to ascertain the structure-affinity relationships (SAR) that govern A 1 and/or A 2A AR affinity as well as the future of the said compounds as synthons by which a range of analogues may be designed for future drug discovery. Fig. 2 The chemical structure and A 1 , A 2A and A 3 K i (h) values of 2

The synthesis of the chalcone derivatives 15-36 and 37-41 was done by a Claisen-Schmidt condensation reaction (Claisen and Claparède 1881; Schmidt 1881) of acetophenone and benzaldehyde using either a base or an acid catalyst in a polar solvent (Fig. 4a , b)-this well-known synthetic route is deemed a classical organic chemistry reaction. As stated, the condensing agents are either strong bases or acids (generally, basic conditions are more common in chalcone synthesis) (Gaonkar and Vignesh 2017; Gomes et al. 2017; Rammohan et al. 2020; Zhuang et al. 2017) ; in the case of base catalysts (15-36), the chalcone is generated from the aldol product via dehydration in an enolate mechanism, while in the case of acid catalysts (37-41), the chalcone is generated via an enol mechanism (Nielsen and Houlihan 2004; Noyce and Pryor 1955) . The Claisen-Schmidt condensation reaction is widespread in the literature because of its experimental simplicity and highly efficient formation of the carbon-carbon double bond. The synthesis of the Schiff base or imine derivatives 42-47 by condensation of 3-aminoacetophenone and different substituted benzaldehydes using a base catalyst in a polar solvent (Fig. 4a )-analogous to the reaction conditions of chalcone derivatives 15-36-was not planned. Initially, it was thought that the said reaction conditions would yield compounds 37-41 and not the regioisomers of these C3 amino-substituted chalcone derivatives comprised of two aromatic rings linked via an azomethine (C=N) group. Schiff base or imine compounds are formed by the reaction of a primary amine (such as 3-aminoacetophenone) and either aldehydes (such as the different substituted benzaldehydes) or ketones with the simultaneous removal of water (Furniss et al. 1989 ). When one, or both, of the reactants are aromatic, the imine is quite stable and usually known as a Schiff base, additionally, in the case of wholly aliphatic reactants the imines tend to decompose or polymerise (Furniss et al. 1989 ). (3), 2-benzylidene-1-tetralone (4-8) and 2-benzylidene-1-indanone (9-12) derivatives Under the adopted synthetic routes, the test compounds 15-36, 37-41 and 42-47 were obtained in fair to good yields, purified by recrystallization from a suitable solvent (EtOH), and in the instance of compounds 37-41 and 42-47, the structure, molecular mass and/or purity of these compounds were verified by 1 H NMR, 13 C NMR, MS and/or HPLC (Supplementary data). The known chalcone derivatives 15-36 were characterized by 1 H NMR only, melting point (DSC) and HPLC and are in accordance with the literature values.

Taking the novel 3-amino-substituted chalcone derivative 38 (R 2 = NH 2 ; R 2′ = Br) as a representative case, the 1 H NMR spectrum displayed two characteristic signals for the ethylenic protons H α (nearer the carbonyl group) and H ß (next to the H α proton) at 7.73 and 7.97 ppm, respectively, as doublets (J Hα,Hß = 15.7 Hz). Protons on the NH 2 -group (similar to the proton on the OH-group) are not always visible on a 1 H NMR spectrum as protons attached to a N-atom (or O-atom) are acidic, and thus, exchangeable. Also, the 13 C NMR spectrum displayed three characteristic signals: a prominent signal for the carbonyl group at 188.36 ppm and two other signals typical of C α (121.39 ppm) and C ß (142.81 ppm).

From the coupling constant value of the ethylenic protons H α and H ß (J Hα,Hß = 15.7 Hz), it may be deduced that compound 38 exists in the trans (E) configuration (Aksöz and Ertan 2012; Barros et al. 2004; Jung et al. 2008; Opletalova et al. 2000; Rao et al. 2001 Rao et al. , 2004 . As a result of the diamagnetic anisotropy (deshielding of proton due to local diamagnetic current) of the carbonyl functional group, the ethylenic proton of the (E) isomer gave a signal at a greater chemical shift than the ethylenic proton of the (Z) isomer, as the latter is more remote from the carbonyl functional group (Bayer et al. 1991) . Stereochemically, a chalcone might exist as either a cis (Z)-or trans (E)-isomer, having two aromatic rings linked via a three carbon α,ß-unsaturated carbonyl system (Gomes et al. 2017; Hallgas et al. 2005) . The cis (Z)conformer is thermodynamically less stable than the trans (E)-conformer due to the steric effects between the carbonyl group and ring A (Hallgas et al. 2005 ; Van der Werten et al. 1995) . The more stable trans (E)-isomer is the predominant configuration among chalcones (Gomes et al. 2017 ). BrNO) . Since Bromine has two isotopes (in a ratio of approximately 1:1), a compound containing a Br-atom (such as compounds 37-38) will have two peaks of similar height in the molecular ion region depending on which bromine isotope the molecular ion contains. Additionally, the two M + molecular ion peaks for compound 38 (C 15 H 12 BrNO) may be seen at 301.0096 ( 79 Br isotope) and 303.0095 ( 81 Br isotope). Of note, chlorine also has two isotopes, namely 35 Cl and 37 Cl (in a ratio of 3:1) meaning a similar effect may be observed on the mass spectrum of an organic compound containing a Cl-atom (for example, compounds 39-40). The purity of compound 38 determined by HPLC was 98.0549%. The melting point of compound 38 determined by DSC was 176.78 °C.

The word chalcone is derived from the Greek word "chalcos", meaning "bronze", which results from the colours of most natural chalcones (Sahu et al. 2012) . The bronze colour of chalcones is most likely due to the reactive keto-ethylenic group CO-CH=CH-; a chromophore responsible for the colour of chalcones depending on the presence of other auxochromes (Gaonkar and Vignesh 2017) . This bronze colour scheme was also observed with most of the synthesised chalcones, for example, the light brown colour of 38.

As stated, the 3-amino-substituted chalcones and the Schiff base derivatives 42-47 are regioisomers (molecules with the same molecular formula, but different bonding patterns and atomic organisations), and as such, dissimilarities were detected on the 1 H NMR and 13 C NMR spectra when comparing these compounds. The absence of the ethylenic protons H α and H ß may be observed on the 1 H NMR spectrum and the signals typical of C α and C ß , on the 13 C NMR. In the place of these signals, the proton adjacent to the azomethine group was visible on the 1 H NMR spectrum and the carbon of the azomethine group on the 13 C NMR spectrum. Additionally, on both the 1 H NMR and 13 C NMR spectra the methyl group from the acetophenone moiety was clearly visible downfield of all other signals.

The degree of binding affinity that the test compounds showed toward rat (r) A 1 and A 2A ARs were determined via radioligand binding assays in either duplicate [specific binding (%)] or triplicate [inhibition constant (K i , µM)] and expressed as either mean or mean ± standard error of the mean (SEM), respectively. Only compounds 24, 29, 37 and 38-which displayed specific binding values < 20% at a maximum tested concentration of 100 µM-justified the determination of inhibition constant values (K i , µM), unlike compounds 15-23, 25-28, 30-36, 39-41 and 42-47 (specific binding values > 20%). The radioligand binding assays were validated with CPA (A 1 agonist), DPCPX (A 1 antagonist) and istradefylline (A 2A antagonist) as reference compounds and results were in accordance with literature values (Table 1) .

As depicted in Tables 2, 3 and 4, most of the test compounds showed poor A 1 and/or A 2A AR affinity upon in vitro evaluation-making it difficult to determine SAR; however, some broad conclusions may be drawn from these results. In brief, the test compounds were noticeably more active against the A 1 AR than A 2A AR and the chalcone derivatives 24, 29, 37 and 38 showed selective A 1 AR affinity below 10 µMof these compounds, 38 had the best A 1 AR affinity (A 1 K i (r) = 1.6 µM). The type of substitution on ring A of the chalcone scaffold played a key role in affinity, and also, the type and position of the substitution on benzylidene ring B.

As stated, the chalcone derivatives 24 (A 1 K i (r) = 5.3 µM) and 29 (A 1 K i (r) = 6.1 µM) ( Table 2) showed selective A 1 AR affinity below 10 µM, and although, the K i (r) values of these compounds were quite similar the substitutions on ring B were not; 24 was C2′, C4′, C5′-trimethoxy substituted and 29 was C2′-chloro substituted. In the past, the antimicrobial (Karaman et al. 2010; Ramyashree et al. 2017) , anticancer (Juvale et al. 2012; Mellado et al. 2018 ) and/or antioxidant (Shenvi et al. 2013 ) activities of compounds 24 and 29 were also explored, and now, selective A 1 AR affinity may be added.

With regard to compound 24 and A 1 AR affinity, it seems that the C2′, C4′, C5′ substitution pattern on ring B was preferred to that of compound 25 ([ 3 H]DPCPX-specific binding (r) = 27%)-interestingly, these compounds differ only at the C5′ (24: -OCH 3 ; 25: -H) and C6′ (24: -H; 25: -OCH 3 ) positions. However, the radioligand-specific binding against the A 2A AR of these compounds were the same (24-25: [ 3 H] NECA-specific binding (r) = 28%). Comparison of 24 to the structurally related 2-benzylidene-1-indanone compound 13 (Fig. 5) consisting of a fused 6-and 5-membered ring system (ring A and ring C, respectively) along with C4′methoxy substitution on ring A had poor A 1 and A 2A AR affinity (Janse van Rensburg et al. 2019b ). The decreased affinity may be due to the increased number of C-, H-and O atoms in the form of the C4 OCH 3 -group substitution on ring A and the CH 2 -group present in ring C, increasing the molecular weight from 298.34 g/mol (24) to 340.38 g/ mol (13), and perhaps, the resultant steric hindrance (of the CH 2 -group present in ring C and C2′ OCH 3 -group on ring B) also decreased binding affinity (Liu et al. 2014; Vásquez-Martínez et al. 2019) . Interestingly, according to the physiochemical properties calculated by the free web-tool Swis-sADME, compound 24 will not be orally bioavailable, but compound 13 will be. Both of these compounds were, unfortunately, not lead-like based on the said parameters. (See "In silico evaluation" for the complete results and discussion).

Comparison of 29 (A 1 K i (r) = 6.1 µM) to 30-31 ([ 3 H] DPCPX-specific binding > 20%) demonstrated the importance of the position of the Cl-atom on ring B for A 1 AR affinity; the C2′ (ortho) position (29) is preferred to the C3′ (meta) and/or C4′ (para) positions (30-31). Additionally, at the C2′ (ortho) position on ring B the more electronegative Cl-atom (29) is favoured over the less electronegative Br-atom (26). (It must be noted that compounds 26-27 and 30 retained some affinity against the A 1 AR based on the specific binding of less than 30%).

These trends were not observed with the C3 amino-substituted chalcone derivatives 37-41 ( Table 3) . Compound 29 paralleled to its counterpart 39 showed decreased A 1 AR affinity (39: [ 3 H]DPCPX-specific binding = 26%); this may be credited to the combination of the NH 2 -group at position C3 on ring A and the Cl-atom at position C2′. Furthermore, C2′ (ortho) Br-group substitution on ring B led to A 1 AR affinity below 10 µM; for example, compound 37 (A 1 K i (r) = 7.1 µM) versus 39 ([3 H ]DPCPX-specific binding = 26%). The A 1 AR affinity was enhanced almost fivefold when the Br-atom was moved from the C2′ position (37) to the C3′ position (38) on ring B. The importance of the C3 NH 2 -group substitution on ring A to attain A 1 AR affinity was demonstrated by comparison of compound 38 to its unsubstituted counterpart 27 ([3 H ]DPCPX-specific binding = 28%). Compound 38 had a K i value of 1.6 µM against the A 1 AR-the best of the evaluated compounds Therefore, it may be said that the A 1 AR favours C3 NH 2 -group substitution on ring A in combination with C3′ Br-atom substitution on ring B; based on these chalcones (15-41). The SAR of the chalcone derivatives 27 and 29 and 37-39 are summarized in Fig. 6 (41)]. (Again, it must be noted that compounds 39-41 retained some affinity against the A 1 AR based on the radioligand-specific binding of less than 30%). The importance of not only the type of k Literature value obtained from (Bruns et al. 1987) l Literature value obtained from (Lohse et al. 1987) m Literature value obtained from (Shimada et al. 1997 

there is likely also steric hindrance to free rotation of the benzylidene ring B of these compounds (37 and 39) (Karton et al. 1996) . Notably, the structurally related 2-benzylidene-1-indanone 14 (Janse van Rensburg et al. 2019a ) that is also C3′ bromo-substituted on benzylidene ring B has selective A 2A AR affinity, unlike compound 38 (Fig. 7) . Therefore, the benzylidene indanone scaffold with C4 hydroxy-substitution on ring A may be essential to selective A 2A AR affinity when compared to the C3 amino-substituted chalcone scaffold. Compound 14 is structurally related to chromone hits with selective A 2A AR affinity based on virtual screening, and perhaps, the conformation of these chromones binding to the A 2A AR is similar to that of compound 14-leading to selectivity of the A 2A AR versus the A 1 AR (Langmead et al. 2012) . Additionally, SAR demonstrated the importance of, among other, the phenol functionality in triazine virtual screening hits for selective A 2A AR affinity; possibly due to the hydrogen bonding between the phenol functionality and Asn253 6.55 (Langmead et al. 2012 ). This key hydrogen bonding residue (Asn253 6.55 ) is situated centrally and capable of high-quality interactions with diverse heterocyclic compounds (Langmead et al. 2012) . Therefore, the phenol functionality (present in compound 14) may also be responsible for the selectivity of the said compound (as seen with the triazine virtual screening hits).

As seen in Table 4 the Schiff base containing compounds 42-47 showed poor A 1 and A 2A AR affinity. The best radioligand-specific binding at a concentration of 100 µM against A 1 and/or A 2A AR was demonstrated by compounds 45 and 47; displacing more than 50% of the radioligand at A 1 (45 and 47) and A 2A (45) ARs. Comparison of 44 to 45 showed that the inclusion of a bromine atom at position C3′ (44), rather than a hydrogen atom (45), in combination with C2′-OH and C5′-Cl substitution on ring B was detrimental to both A 1 and A 2A AR affinity as the radioligand-specific binding increased more than twofold. The A 1 AR seemed to be more tolerable toward the said substitution. Schiff base or imine derivatives are important synthetic intermediates (Furniss et al. 1989 ); therefore, the synthesised and evaluated compounds 42-47 may be of use in future studies.

The type of binding affinity that test compounds 24 and 38 exhibited at the rat A 1 AR was determined via a GTP shift assay, as described previously (Lohse et al. 1987 ; Van der Walt and Terre'Blanche 2015; Van der Werten et al. 1995) . GTP shifts were calculated by dividing the K i values of compounds reported in the presence of GTP by the K i values obtained in the absence of GTP and the results are summarized in Table 5 .

Test compounds 24 and 38 were selected as they possessed the highest A 1 AR affinity in the three respective series (Tables 2, 3, 4) . The results suggested that compounds 24 and 38 acted as A 1 AR antagonists, as the binding curves in the presence of GTP were almost unaffected and the calculated GTP shifts were approximately 1 (Table 5 ; Fig. 8 ) (Van der Werten et al. 1995; Gütschow et al. 2012 ). On account of the structural similarity of the test compounds (15-23, 25-36, 37 and 39-41), it may be supposed that these chalcone derivatives were all A 1 AR antagonists.

The physiochemical, pharmacokinetic as well as drug-likeness and medicinal chemistry friendliness of compounds 24, 29, 37 and 38 (the only test compounds with selective A 1 AR affinity) were computed via SwissADME and these results are summarized in Tables 6, 7 and 8, respectively.

The bioavailability radar (Fig. 9 ) gave a first glance at the drug-likeness of these compounds; compounds 24, 29, 37 and 38 fall within the optimal range for the parameters lipophilicity, size, polarity, solubility and flexibility (see Table 6 ), except for saturation (Csp 3 > 0.25). The fraction of carbon atoms in the sp 3 hybridization of compounds 24 (logS)]. This was encouraging given the poor solubility of most chalcone-based compounds [most probably the reason for poor in vivo efficacy in preclinical studies (Zhuang et al. 2017) ]. Seeing as solubility influences GI absorption (Ottaviani et al. 2010 ), a soluble molecule will most probably facilitate drug development (Ritchie et al. 2013) . The BOILED-Egg model (Fig. 10) predicted passive human gastrointestinal absorption (HIA) and blood-brainbarrier (BBB) permeation as a function of the position of the compound in the WLOGP-versus-TPSA referential (Daina and Zoete 2016) . Compounds 24, 29, 37 and 38 were predicted to have high GI absorption and permeate the BBB Fig. 6 The structure-affinity relationships (SAR) of compounds 27 and 29 and 37-39; highlighting the importance of C3 NH 2 -substitution on ring A in combination with C3′ (meta) Br substitution on ring B for selective rA 1 AR affinity Fig. 7 The structure-affinity relationships (SAR) of compound 38 versus 14 (Table 7) . Additionally, these compounds were not substrates for the permeability glycoprotein (Pgp) responsible for efflux through biological membranes, for instance from the gastrointestinal wall to the lumen or from the brain (Montanari and Ecker 2015) . Pgp also protects the CNS from xenobiotics (Szakács et al. 2008) .

The interaction of a compound with cytochromes P450 (CYP) is important; seeing as these isoenzymes modulate drug elimination through metabolic transformation (Testa and Kraemer 2007) ; probably causing pharmacokineticsrelated drug-drug interactions (Hollenberg 2002; Huang et al. 2008 ), leading to adverse or even toxic effects due to the lower clearance and accumulation of the drug or its metabolites (Kirchmair et al. 2015) . Compounds 24, 29, 37 and 38 were predicted to inhibit the major CYP isoforms (CYP12, CYP2C19, CYP2C9, CYP2D6 and CYP3A4), with the exception of 24 and/or 37-38 that did not inhibit CYP2D6 (29 and 37-38) and CYP3A4 (29).

The drug-likeness of compounds 24, 29, 37 and 38 was assessed by various rule-based filters (Egan et al. 2000; Ghose et al. 1999; Lipinski et al. 1997; Muegge et al. 2001; Veber et al. 2002) (Table 8) . Compound 29 violated a rule-based filter from Muegge (Muegge et al. 2001) ; namely that a compound should contain more than one heteroatom and the only atom other than carbon and hydrogen that 29 contained was a chloro atom. Additionally, compounds 24, 29, 37 and 38 all had a bioavailability score of 0.55 (the probability that a compound will have > 10% bioavailability in rat or measurable Caco-2 permeability) (Martin 2005) .

The medicinal chemistry friendliness of compounds 24, 29, 37 and 38 was assessed by the identification of potentially problematic fragments; first, pan assay interference compounds (PAINS) (Baell and Holloway 2010) and, second, structural alerts (Brenk et al. 2008) . Compounds 24, 29, 37 and 38 contained no PAINS; however, Brenk violations were present (Table 8 ). All these compounds contained an α,ß-unsaturated carbonyl system perceived as a potential Michael acceptor. Additionally, compounds 37-38 contained a potentially unwanted aniline group; as aniline groups are perhaps inclined toward problems with genetic toxicity (Clayson 1981) .

As compounds 24, 29, 37 and 38 did not have pronounced affinity toward the A 1 AR, the present structures need to be optimised, and here, lead-likeness [a molecular entity suitable for optimization, most probably increasing size and lipophilicity (Hann and Keserü 2012) ] plays a role (Teague et al. 1999) . Accordingly, compounds 24, 37 and 38 (but not compound 29; due to molecular weight value smaller than 250 g/mol and consensus logP o/w value larger than 3.5) may be considered lead-like (Tables 6, 8) . Therefore, the optimization of the physiochemical properties of chalcones and, thus, the pharmacokinetic properties as well as drug-likeness and medicinal chemistry friendliness is of great importance for medicinal chemistry research on chalcone-based compounds.

Unless otherwise noted, all starting materials and solvents were purchased from commercial vendors and used without further purification. Thin layer chromatography on TLC silica gel 60 F 254 aluminium sheets from Merck was used to monitor reaction progress. Melting points were determined by means of differential scanning calorimetry (DSC) with a Mettler DSC 3 Star System (Mettler Toledo, Greifensee, Switzerland). Proton ( 1 H) and carbon ( 13 C) nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance III 600 spectrometer at frequencies of 600 and 151 MHz, respectively, using either CDCl 3 or DMSO-d6 as solvent and TMS as reference. Chemical shifts were reported in parts per million (ppm) in relation to the solvent peak (CDCl 3 : residual CH at 7.26 ppm and DMSO-d6: residual CH 3 at 2.50 ppm for 1 H NMR). Spin multiplicities were indicated as follows: singlet (s), doublet (d), triplet (t), quartet (q), doublet of doublets (dd), triplet of doublets (td), double double doublet (ddd) and multiplet (m). Coupling constant (J) values were reported in Hertz (Hz). High-resolution mass spectra (HRMS) were recorded on a Bruker micrOTOF-Q II mass spectrometer in atmospheric chemical ionisation (APCI) mode. High-performance liquid chromatography (HPLC) analyses were done on an Agilent 1100 HPLC system.

A solution of acetophenone (0.50 g, 4.16 mmol) and benzaldehyde (0.44 g, 4.16 mmol) in EtOH (5 mL) was mechanically stirred at room temperature for approximately 5 min before the dropwise addition of KOH (10% (w/v) aqueous solution, 5 mL). The subsequent reaction mixture was mechanically stirred at room temperature and continuously monitored by TLC. Upon completion, the reaction mixture was quenched with crushed ice (15 g) and acidified to pH 2 with HCl (32 wt. % in H 2 O, FCC). The subsequent precipitate was collected by vacuum filtration, dried (30 °C) and recrystallized from 

prop-2-en-1-one (33) Prepared as for 15 from acetophenone (0.50 g, 4.16 mmol) and 4-(trifluoromethyl)benzaldehyde ( (Nagarajan and Shechter 1984) . Purity (HPLC): 94.7%.

( 30, 141.78, 138.30, 133.80, 133.34, 132.35, 130.19, 128.76, 128.26, 126.55, 126.49, 125.44, 124.70, 121.31 39, 142.86, 138.41, 136.78, 133.81, 130.73, 130.32, 130.16, 128.05, 127.90, 126.61, 126.56, 123.36, 121.40 163.28, 161.67, 143.14, 138.43, 137.12, 137.07, 135.17, 130.93, 130.88, 130.19, 126.74, 126.66, 125.61, 123.29, 121.54, 117.54, 117.40, 114.83, 114.69 161.58, 156.92, 147.57, 138.65, 136.12, 130.85, 130.11, 127.76, 126.39, 124.20, 120.40, 120.01, 112. 

The collection of tissue samples for the A 1 and A 2A AR radioligand binding assays were approved by the Health Sciences Ethics Office for Research, Training and Support, North-West University (application number NWU-00260-17-A5) and were performed in accordance with the guidelines of the South African National Standard (SANS) document (The care and use of animals for scientific purposes).

Male Sprague-Dawley rats were dissected to attain rat whole brain membranes (excluding cerebellum and brain stem) and rat striatal membranes for the A 1 and A 2A AR radioligand binding assays, respectively. Tissue samples were prepared and stored as described in literature (Van der Walt and Terre'Blanche 2015). Protein concentrations were determined according to the Bradford assay, using bovine serum albumin as reference standard (Bradford 1976 ).

The degree of binding affinity the test compounds possess towards rat A 1 and A 2A ARs were determined via radioligand binding assays, as described previously (Bradford 1976; Bruns 1987; Bruns and Watson 2012 ; Van der Walt and Terre'Blanche 2015). The A 1 AR radioligand binding assay used rat whole brain membranes (expressing A 1 ARs) and 0.1 nM 1,3-[ 3 H]-dipropyl-8-cyclopentylxanthine ([ 3 H] DPCPX) as radioligand (Bruns 1987 ) and, in turn, the A 2A AR radioligand binding assay used rat striatal membranes (expressing A 2A ARs) and 4 nM 5′-N-ethylcarboxamido[ 3 H] adenosine ([ 3 H]NECA) as radioligand (Bruns et al. 1986 ). N 6 -Cyclopentyladenosine (CPA) was also added to the A 2A AR radioligand binding assay (in order to eliminate the A 1 component of binding exhibited by the non-selective [ 3 H] NECA) as well as MgCl 2 (in order to increase radioligand binding and decrease non-specific binding) (Bruns et al. 1986 (Bruns et al. 1986 ; Van der Walt and Terre'Blanche 2015). Specific binding was defined as the total binding minus the non-specific binding (Van der Walt and Terre'Blanche 2015).

The type of binding affinity test compounds exhibited at the rat A 1 AR was determined via a guanosine triphosphate (GTP) shift assay, as described previously (Lohse et al. 1987 ; Van der Walt and Terre'Blanche 2015; Van der Werten et al. 1995) . A GTP shift assay resembles the A 1 AR radioligand binding assay. However, it requires the addition of 100 µM GTP. Non-specific binding was defined as binding in the presence of 10 µM DPCPX ( Van der Werten et al. 1995; Lohse et al. 1984) .

In short, all statistical data analyses were done using Microsoft Excel and GraphPad Prism Software. Sigmoidal dose response curves, from which IC 50 values were calculated, were obtained by plotting the specific binding against the logarithm of the test compounds' concentrations. Subsequently, the IC 50 values were used to calculate the K i values for the competitive inhibition of [ 3 H]DPCPX (K d = 0.36 nM) against rat whole brain membranes and [ 3 H] NECA (K d = 15.3 nM) against rat striatal membranes by the test compounds by means of the Cheng-Prusoff equation. All calculated K i values were determined in triplicate and given as mean ± standard error of the mean (SEM). Specific binding (%) of the radioligand at a maximum tested concentration of 100 µM were determined in duplicate and expressed as the mean in %. SI index values were calculated as a ratio of the A 1 and A 2A AR K i values of test compounds. GTP shifts were calculated by dividing the K i values of compounds reported in the presence of GTP by the K i values obtained in the absence of GTP.

SwissADME (https ://www.swiss adme.ch), a free web tool, was used to evaluate key parameters of small molecules; such as pharmacokinetics, drug-likeness and medicinal chemistry friendliness. Pharmacokinetic parameters (absorption, distribution, metabolism and excretion), among others, were predicted from molecular structures using the most relevant computational methods, and thus, do not focus on just one specific property or model (Daina et al. 2017 ).

A total of 33 chalcones (15-36 and 37-41) and structurally related compounds (42-47) with different substitutions on ring A and/or benzylidene ring B were synthesised, characterized and evaluated in vitro to determine the degree and type of A 1 and A 2A receptor binding. While most compounds were not novel, the application of all compounds is original. The chalcone derivatives 24, 29, 37 and 38 possessed selective A 1 affinity below 10 µM; compound 38 was the most potent selective A 1 AR antagonist (K i (r) = 1.6 µM). Most of the test compounds showed poor A 1 and/or A 2A AR affinity upon in vitro evaluation-making it difficult to determine SARs; however, some broad conclusions were drawn from these results. The type of substitution on ring A of the chalcone scaffold played a key role in affinity, and the position of the substitution on benzylidene ring B; the NH 2 -group at position C3 of ring A of the chalcone scaffold, and the Br-atom at position C3′ on benzylidene ring B were essential to selective A 1 AR affinity (exemplified by compound 27 versus 38 and 37 versus 38). Selective A 1 AR affinity and antagonistic activity may be added to the known biological activities of compounds 24 and 29. The physiochemical and pharmacokinetic properties (based on in silico evaluation) proved the chalcone derivatives 24, 29, 37 and 38, although drug-like, not at all lead-like (29). Thus far, the chalcone chemical structure was a promising scaffold in medicinal chemistry; due to the diverse chemistry and biology of this α,ß-unsaturated carbonyl system. The said system may be troublesome (it is perceived as a potential Michael acceptor); however, it easily allows structural modification and introduction of a heterocyclic ring system (such as isoxazole, pyrazole, pyrrole etcetera) which may just be beneficial to A 1 and/ or A 2A AR binding affinity; thus, leading to the discovery of new pharmacophores from this classes of compounds.

Depression in Parkinson disease-epidemiology, mechanisms and management

Spectral properties of chalcones II

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays

Synthesis, experimental and theoretical NMR study of 2′-hydroxychalcones bearing a nitro substituent on their B ring

Trends in utilization of the pharmacological potential of chalcones

New aromatase inhibitors. Synthesis and biological activity of pyridyl-substituted tetralone derivatives

Regulation of extracellular adenosine

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Lessons learnt from assembling screening libraries for drug discovery for neglected diseases

Binding of the A 1-selective adenosine antagonist 8-cyclopentyl-1, 3-dipropylxanthine to rat brain membranes

Rules for identifying potentially reactive or promiscuous compounds

Characterization of the A2 adenosine receptor labeled by [3H] NECA in rat striatal membranes

Synthesis and algicidal activity of new dichlorobenzylamine derivatives against harmful red tides

Condensationen von Ketonen mit Aldehyden

schol ar?hl=en&as_sdt=0%2C5&q=Clays on+DB+%28198 1%29+Aroma tic+amine s%3A+an+asses sment +of+the+biolo gical +and+envir onmen tal+effec ts

A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules

SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

Adenosine A2A receptor as a drug discovery target

Tissue distribution of adenosine receptor mRNAs in the rat

Chalcone and cinnamate synthesis via one-pot enol silane formation-Mukaiyama aldol reactions of ketones and acetate esters

The physiological role of adenosine in the central nervous system

Prediction of drug absorption using multivariate statistics

VI. Nomenclature and classification of purinoceptors

International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update

Interactions of the bovine brain A1-adenosine receptor with recombinant G protein alpha-subunits

ar?hl=en&as_sdt=0%2C5&q=Freis smuth +M%2C+Sch%C3%BCtz+W%2C+Linde r+M+%28199 1%29+Inter actio ns+of+the+bovin e+brain +A1-adeno sine+recep tor+with+recom binan t+G+prote in+alpha -subun its.+Selec tivit y+for+rGi+alpha -3+Journ al+of+Biolo gical +Chemi stry+266%3A177

Vogel's textbook of practical organic chemistry, 5th edn. Longman Group UK Limited

Synthesis and pharmacological properties of chalcones: a review

The effects of adenosine ligands R-PIA and CPT on ethanol withdrawal

A knowledgebased approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1 A qualitative and quantitative characterization of known drug databases

Chalcone derivatives: promising starting points for drug design

Benzothiazinones: a novel class of adenosine receptor antagonists structurally unrelated to xanthine and adenine derivatives

Characterization of lipophilicity and antiproliferative activity of E-2-arylmethylene-1-tetralones and their heteroanalogues

Finding the sweet spot: the role of nature and nurture in medicinal chemistry

Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes

New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process

Cholinergic system

Adenosine receptors as therapeutic targets

Interactions of flavones and other phytochemicals with adenosine receptors. Flavonoids in cell function

Anxiolytic activity of adenosine receptor activation in mice

5-Substituted 2-benzylidene-1-tetralone analogues as A1 and/or A2A antagonists for the potential treatment of neurological conditions

2-benzylidene-1-indanone analogues as dual adenosine A1/A2a receptor antagonists for the potential treatment of neurological conditions

Methoxy substituted 2-benzylidene-1-indanone derivatives as A1 and/or A2A AR antagonists for the potential treatment of neurological conditions

Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor

Ferrocenyl chalcones containing anthracenyl group: synthesis, X-ray crystal structures and electrochemical properties

Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein

Effects of benzodiazepine administration on A1 adenosine receptor binding in-vivo and ex-vivo

Screening of biological activities of a series of chalcone derivatives against human pathogenic microorganisms

Advances in chalcones with anticancer activities

Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists

Bioactive Benzofuran derivatives: a review

Predicting drug metabolism: experiment and/or computation?

Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells

F r e d h o l m + B % 2 C + L o h s e + M + % 2 8 1 9 9 7 % 2 9 + C o mp a ra t i v e+pharm acolo gy+of+human +adeno sine+recep tor+subty pes%E2%80%93cha racte rizat ion+of+stabl y+trans fecte d+recep tors+in+CHO+cells +Nauny n-Schmi edebe rg%27s+archi ves+of+pharm acolo

Identification of novel adenosine A2A receptor antagonists by virtual screening

Evaluation of 2-benzylidene-1-tetralone derivatives as antagonists of A1 and A2A adenosine receptors

Silver-catalyzed efficient synthesis of enaminones from propargyl alcohols and amines

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Comparative binding affinities of flavonoid phytochemicals with bovine serum albumin

Interaction of barbiturates with adenosine receptors in rat brain

8-Cyclopentyl-1, 3-dipropylxanthine (DPCPX)-a selective high affinity antagonist radioligand for A 1 adenosine receptors

Subclasses of external adenosine receptors

Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists

Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors

A bioavailability score

Perspective design of chalcones for the management of CNS disorders: a mini-review

A graphical journey of innovative organic architectures that have improved our lives

Synthesis of chalcones with antiproliferative activity on the SH-SY5Y neuroblastoma cell line: quantitative structure-activity relationship models

Prediction of drug-ABC-transporter interaction-recent advances and future challenges

Simple selection criteria for drug-like chemical matter

A1 adenosine receptors and their ligands: overview and recent developments

A1 adenosine receptors of bovine brain couple to guanine nucleotide-binding proteins Gi1, Gi2, and Go

The diverse carbenic and cationic chemistry of 3-diazo-2, 5-diphenylpyrrole

Effect of istradefylline on mood disorders in Parkinson's disease

Adenosine uptake inhibitors

N6-cyclopentyladenosine impairs passive avoidance retention by selective action at A1 receptors

Carbonyl reactions. I. Kinetics and mechanism of the acid-catalyzed aldol condensation of benzaldehyde and acetophenone1

Conformational analysis of 2-hydroxy-2′, 5′-diazachalcones

What is modulating solubility in simulated intestinal fluids

Adenosine and adenine nucleotides as regulators of cellular function

The adenosine A1 receptor antagonist BIIP 20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat

Receptors for purines and pyrimidines

Chalcone synthesis, properties and medicinal applications: a review

Synthesis, characterization and antimicrobial activities of chalcones and their post transformation to pyrazole derivatives

Novel synthesis of macrocycles with chalcone moieties through mixed aldol reaction

Differential effects of synthesized 2′-oxygenated chalcone derivatives: modulation of human cell cycle phase distribution

Subcellular localization of adenosine A1 receptors in nerve terminals and synapses of the rat hippocampus

Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord

Increasing small molecule drug developability in sub-optimal chemical space

2-Aminopyrimidines as dual adenosine A1/A2A antagonists

The synthesis of chalcones as anticancer prodrugs and their bioactivation in CYP1 expressing breast cancer cells

Exploring pharmacological significance of chalcone scaffold: a review

Neuronal exocytosis. Protein trafficking in neurons

Structure−activity relationships of methoxychalcones as inducers of heme oxygenase-1

Ueber die Einwirkung von Aceton auf Furfurol und auf Bittermandelöl bei Gegenwart von Alkalilauge

Synthesis, anticancer and antioxidant activities of 2, 4, 5-trimethoxy chalcones and analogues from asaronaldehyde: structure-activity relationship

Adenosine A2A antagonists with potent anticataleptic activity

Recent developments in biological activities of chalcones: a mini review

5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure−activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds

Design and synthesis of chalcone derivatives as inhibitors of the ferredoxin-ferredoxin-NADP+ reductase interaction of plasmodium falciparum: pursuing new antimalarial agents

Structureactivity relationships on amelioration against scopolamineor N6-[(R)-phenylisopropyl] adenosine-induced cognitive disturbance

Adenosine A1 receptors are located predominantly on axons in the rat hippocampal formation

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox)

DPCPX, a selective adenosine A1 receptor antagonist, enhances the antidepressant-like effects of imipramine, escitalopram, and reboxetine in mice behavioral tests

Agomelatine and tianeptine antidepressant activity in mice behavioral despair tests is enhanced by DMPX, a selective adenosine A2A receptor antagonist, but not DPCPX, a selective adenosine a1 receptor antagonist

The design of leadlike combinatorial libraries

The biochemistry of drug metabolism-an introduction-testa-2007-chemistry and biodiversity-Wiley Online Library

Palladium-catalyzed decarboxylative arylation of benzoylacrylic acids toward the synthesis of chalcones

Adenosine inhibits the accumulation of cyclic AMP in cultured brain cells

8-Substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A1 receptor

Chalcone-based derivatives as new scaffolds for h A 3 adenosine receptor antagonists

Molecular properties that influence the oral bioavailability of drug candidates

Chronic treatment with DCPCX, an adenosine A1 antagonist, worsens long-term memory

Effects of chronic administration of adenosine A1 receptor agonist and antagonist on spatial learning and memory

Intermolecular multiple dehydrogenative cross-couplings of ketones with boronic acids and amines via copper catalysis

Silver-catalyzed decarboxylative cross-coupling of α-keto acids with alkenes giving approach to chalcones

Synthesis and evaluation of hydroxychalcones as multifunctional non-purine xanthine oxidase inhibitors for the treatment of hyperuricemia

Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice

Silver-catalyzed double-decarboxylative cross-coupling of α-keto acids with cinnamic acids in water: a strategy for the preparation of chalcones

Diverse molecular targets for chalcones with varied bioactivities

Phosphorous acid promoted hydration-condensation of aromatic alkynes with aldehydes affording chalcones in an oil/ water two-phase system

Chalcone: a privileged structure in medicinal chemistry

Acknowledgements This study was funded by the National Research Foundation (NRF) of South Africa (Grant number 111814) and the North-West University (NWU). The authors wish to thank Dr D. Otto for NMR analyses and Dr J. Jordaan for MS analyses both from Chemical Research Beneficiation at NWU, as well as Prof. W. Liebenberg for DSC analyses, Prof F. Van der Kooy for HPLC analyses and Ms S. Lowe for assistance with biological assays from the Centre of Excellence for Pharmaceutical Sciences (Pharmacen), NWU.

The authors declare no conflict of interest.